Reblozyl Euroopa Liit - itaalia - EMA (European Medicines Agency)

reblozyl

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - altre antianemico preparazioni - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

Zeposia 0.23 mg Capsule rigide Šveits - itaalia - Swissmedic (Swiss Agency for Therapeutic Products)

zeposia 0.23 mg capsule rigide

bristol-myers squibb sa - ozanimodum - capsule rigide - ozanimodum 0.23 mg ut ozanimodi hydrochloridum 0.25 mg, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 0.187 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172, drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172, pro capsula. - multiple sklerose, colitis ulcerosa - synthetika

Zeposia 0.46 mg Capsule rigide Šveits - itaalia - Swissmedic (Swiss Agency for Therapeutic Products)

zeposia 0.46 mg capsule rigide

bristol-myers squibb sa - ozanimodum - capsule rigide - ozanimodum 0.46 mg ut ozanimodi hydrochloridum 0.5 mg, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 0.187 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172, drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172, pro capsula. - multiple sklerose, colitis ulcerosa - synthetika

Zeposia 0.92 mg Capsule rigide Šveits - itaalia - Swissmedic (Swiss Agency for Therapeutic Products)

zeposia 0.92 mg capsule rigide

bristol-myers squibb sa - ozanimodum - capsule rigide - ozanimodum 0.92 mg ut ozanimodi hydrochloridum 1, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 0.187 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172, drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172, pro capsula. - multiple sklerose, colitis ulcerosa - synthetika

Inrebic Euroopa Liit - itaalia - EMA (European Medicines Agency)

inrebic

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - agenti antineoplastici - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Inrebic 100 mg Capsule rigide Šveits - itaalia - Swissmedic (Swiss Agency for Therapeutic Products)

inrebic 100 mg capsule rigide

bristol-myers squibb sa - fedratinibum - capsule rigide - fedratinibum 100 mg ut fedratinibi dihydrochloridum monohydricum, cellulosum microcristallinum silicificatum, natrii stearylis fumaras corresp. natrium 0.18 mg, kapselhülle: gelatina, e 172 (rubrum), e 171, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - primäre oder sekundäre myelofibrose - synthetika

Lenalidomid BMS 2,5 mg Capsule rigide Šveits - itaalia - Swissmedic (Swiss Agency for Therapeutic Products)

lenalidomid bms 2,5 mg capsule rigide

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 2.5 mg, lactosum 73.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.2 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), e 132, drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Lenalidomid BMS 5 mg Capsule rigide Šveits - itaalia - Swissmedic (Swiss Agency for Therapeutic Products)

lenalidomid bms 5 mg capsule rigide

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 5 mg, lactosum 147 mg, cellulosum microcristallinum, carmellosum natricum solo tenuti insieme corrisp. sodio 0,4 mg, magnesio stearas, kapselhülle: gelatina, e-171, drucktinte: lacca, propylenglycolum, e 172 (nero), kalii hydroxidum, per una piccola scatola. - onkologikum - synthetika

Lenalidomid BMS 7,5 mg Capsule rigide Šveits - itaalia - Swissmedic (Swiss Agency for Therapeutic Products)

lenalidomid bms 7,5 mg capsule rigide

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 7.5 mg, lactosum 144.5 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.4 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika

Lenalidomid BMS 10 mg Capsule rigide Šveits - itaalia - Swissmedic (Swiss Agency for Therapeutic Products)

lenalidomid bms 10 mg capsule rigide

bristol-myers squibb sa - lenalidomidum - capsule rigide - lenalidomidum 10 mg, lactosum 294 mg, cellulosum microcristallinum, carmellosum natricum conexum corresp. natrium 0.8 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 132, e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - onkologikum - synthetika